GlaxoSmithKline says that some of its executives appear to have violated Chinese laws. In response, the company is pledging changes in the way it operates — which would bring down the prices of some of its drugs in China. Chinese authorities accuse the company of bribing doctors and officials to boost sales and raise the price of medicines.
GlaxoSmithKline Says Executives May Have Broken Chinese Laws
By editor • Jul 22, 2013
Originally published on July 22, 2013 6:30 am